vs
Side-by-side financial comparison of ARROWHEAD PHARMACEUTICALS, INC. (ARWR) and Borr Drilling Ltd (BORR). Click either name above to swap in a different company.
Borr Drilling Ltd is the larger business by last-quarter revenue ($267.7M vs $264.0M, roughly 1.0× ARROWHEAD PHARMACEUTICALS, INC.). Borr Drilling Ltd runs the higher net margin — 13.1% vs 11.7%, a 1.4% gap on every dollar of revenue. On growth, ARROWHEAD PHARMACEUTICALS, INC. posted the faster year-over-year revenue change (10461.3% vs -1.5%).
Arrowhead Pharmaceuticals, Inc. is a publicly traded biopharmaceutical company based in Pasadena, California. Arrowhead's products in development act through RNA interference (RNAi) mechanisms of action. The company focuses on treatments for hepatitis B, liver disease associated with alpha 1-antitrypsin deficiency and cardiovascular disease.
Borr Drilling Ltd is a global offshore drilling contractor owning and operating a modern fleet of high-spec jack-up rigs. It offers drilling services to oil and gas exploration and production firms, with main operations across the North Sea, Southeast Asia, Middle East, and West Africa for shallow-water and marginal field projects.
ARWR vs BORR — Head-to-Head
Income Statement — Q1 FY2026 vs Q2 FY2025
| Metric | | |
|---|---|---|
| Revenue | $264.0M | $267.7M |
| Net Profit | $30.8M | $35.1M |
| Gross Margin | — | — |
| Operating Margin | 15.5% | 36.0% |
| Net Margin | 11.7% | 13.1% |
| Revenue YoY | 10461.3% | -1.5% |
| Net Profit YoY | 117.8% | 10.7% |
| EPS (diluted) | $0.22 | $0.14 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $264.0M | — | ||
| Q2 25 | — | $267.7M | ||
| Q2 24 | — | $271.9M | ||
| Q2 23 | — | $187.5M | ||
| Q2 22 | — | $105.3M |
| Q4 25 | $30.8M | — | ||
| Q2 25 | — | $35.1M | ||
| Q2 24 | — | $31.7M | ||
| Q2 23 | — | $800.0K | ||
| Q2 22 | — | $-165.3M |
| Q4 25 | 15.5% | — | ||
| Q2 25 | — | 36.0% | ||
| Q2 24 | — | 38.4% | ||
| Q2 23 | — | 31.9% | ||
| Q2 22 | — | -116.8% |
| Q4 25 | 11.7% | — | ||
| Q2 25 | — | 13.1% | ||
| Q2 24 | — | 11.7% | ||
| Q2 23 | — | 0.4% | ||
| Q2 22 | — | -157.0% |
| Q4 25 | $0.22 | — | ||
| Q2 25 | — | $0.14 | ||
| Q2 24 | — | $0.12 | ||
| Q2 23 | — | $0.00 | ||
| Q2 22 | — | $-1.09 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $715.0M | $92.4M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $568.4M | $1.0B |
| Total Assets | $1.6B | $3.4B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $715.0M | — | ||
| Q2 25 | — | $92.4M | ||
| Q2 24 | — | $195.3M | ||
| Q2 23 | — | $83.8M | ||
| Q2 22 | — | $29.7M |
| Q4 25 | — | — | ||
| Q2 25 | — | — | ||
| Q2 24 | — | — | ||
| Q2 23 | — | — | ||
| Q2 22 | — | $281.8M |
| Q4 25 | $568.4M | — | ||
| Q2 25 | — | $1.0B | ||
| Q2 24 | — | $999.2M | ||
| Q2 23 | — | $906.2M | ||
| Q2 22 | — | $711.5M |
| Q4 25 | $1.6B | — | ||
| Q2 25 | — | $3.4B | ||
| Q2 24 | — | $3.2B | ||
| Q2 23 | — | $3.0B | ||
| Q2 22 | — | $3.0B |
| Q4 25 | — | — | ||
| Q2 25 | — | — | ||
| Q2 24 | — | — | ||
| Q2 23 | — | — | ||
| Q2 22 | — | 0.40× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $13.5M | $6.3M |
| Free Cash FlowOCF − Capex | $11.3M | — |
| FCF MarginFCF / Revenue | 4.3% | — |
| Capex IntensityCapex / Revenue | 0.8% | — |
| Cash ConversionOCF / Net Profit | 0.44× | 0.18× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $13.5M | — | ||
| Q2 25 | — | $6.3M | ||
| Q2 24 | — | $16.0M | ||
| Q2 23 | — | $2.4M | ||
| Q2 22 | — | $-8.5M |
| Q4 25 | $11.3M | — | ||
| Q2 25 | — | — | ||
| Q2 24 | — | — | ||
| Q2 23 | — | — | ||
| Q2 22 | — | — |
| Q4 25 | 4.3% | — | ||
| Q2 25 | — | — | ||
| Q2 24 | — | — | ||
| Q2 23 | — | — | ||
| Q2 22 | — | — |
| Q4 25 | 0.8% | — | ||
| Q2 25 | — | — | ||
| Q2 24 | — | — | ||
| Q2 23 | — | — | ||
| Q2 22 | — | — |
| Q4 25 | 0.44× | — | ||
| Q2 25 | — | 0.18× | ||
| Q2 24 | — | 0.50× | ||
| Q2 23 | — | 3.00× | ||
| Q2 22 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ARWR
Segment breakdown not available.
BORR
| Transferred Over Time | $256.6M | 96% |
| Transferred At Point In Time | $11.1M | 4% |
